Arcus Biosciences
RCUS
187 hedge funds and large institutions have $763M invested in Arcus Biosciences in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 99 increasing their positions, 29 reducing their positions, and 31 closing their positions.
241% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 29
175% more capital inflows, than outflows
Capital inflows: $223M | Capital outflows: $81.2M
5% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $1.03M
3% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 31
1% more funds holding
Funds holding: 186 → 187 (+1)
0.15% more ownership
Funds ownership: 91.71% → 91.86% (+0.15%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Suvretta Capital Management
New York
|
+$23M |
| 2 |
Woodline Partners
San Francisco,
California
|
+$18.6M |
| 3 |
Gilead Sciences
Foster City,
California
|
+$15.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.1M |
| 5 |
BlackRock
New York
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boxer Capital Management
San Diego,
California
|
-$23.9M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$16.1M |
| 3 |
Braidwell
Stamford,
Connecticut
|
-$11.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.6M |
| 5 |
Readystate Asset Management
Chicago,
Illinois
|
-$5.23M |
RCUS Hedge Fund Activity: Q1 2025 in Review
187 of the 7,488 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2025, worth a combined $763M — down 39% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new RCUS positions and 31 closed out — a net gain of 1 holder — while 99 added to existing stakes and 29 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $23M. The largest seller was Boxer Capital Management, exiting entirely with an estimated $23.9M sold.
- 187 institutional investors held Arcus Biosciences (RCUS) as of Q1 2025, up from 186 in Q4 2024.
- Funds reported $763M of Arcus Biosciences stock for Q1 2025, down 39% quarter-over-quarter.
- 32 funds opened new Arcus Biosciences positions in Q1 2025 and 31 closed out, a net change of +1 holder.
- The largest Arcus Biosciences buyer in Q1 2025 was Suvretta Capital Management, an estimated $23M added.
- The largest Arcus Biosciences seller in Q1 2025 was Boxer Capital Management, an estimated $23.9M sold.
Based on aggregated 13F filings for Q1 2025.